Voloridge Investment Management

Voloridge Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Voloridge Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.7M	Sell	540,511 -373,509	-41%	-$9.53M	0.05%	445
2025 Q4	$26.5M	Buy	914,020 +80,530	+10%	+$2.06M	0.09%	273
2025 Q3	$15.7M	Buy	+833,490	New	+$13.1M	0.05%	419
2025 Q2	–	Sell	-77,035	Closed	-$1.2M	–	1157
2025 Q1	$1.2M	Sell	77,035 -213,903	-74%	-$3.01M	﹤0.01%	1023
2024 Q4	$4.05M	Buy	290,938 +162,495	+127%	+$1.78M	0.01%	825
2024 Q3	$1.19M	Sell	128,443 -434,728	-77%	-$4.29M	﹤0.01%	1007
2024 Q2	$5.24M	Sell	563,171 -380,296	-40%	-$3.44M	0.02%	735
2024 Q1	$9.35M	Buy	+943,467	New	+$7.04M	0.03%	503

Other funds holding ARQT

Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return